[breadcrumb_custom]

CRVS’s Stock Market Adventure: 25.85% YTD Growth Amidst Volatility

Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The metric has seen a significant gain of 25.85% since the start of this calendar year. Looking back over the last six months, we can see a weaker performance of 3.50%. Over the past 30 days, the price of CRVS has leaped by -0.23%. And in the last five days, it has surged by 5.48%.

Corvus Pharmaceuticals Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $4.19 on 06/09/23, while the lowest price for the same duration was marked at $0.61 on 03/28/23.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

52-week price history of CRVS Stock

Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Corvus Pharmaceuticals Inc’s current trading price is -47.14% away from its 52-week high, while its distance from the 52-week low is 264.91%. The stock’s price range during this time has been between $0.61 and $4.19. The trading volume for the Healthcare sector company’s shares reached about 203.55 for the day, which was higher than the average daily volume of 5.04 over the last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Corvus Pharmaceuticals Inc (CRVS) has experienced a quarterly rise of 38.44% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 108.62M.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 1.64, with a change in price of +0.66. Similarly, Corvus Pharmaceuticals Inc recorded 204,214 in trading volume during the last 100 days, posting a change of +42.90%.

CRVS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRVS stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.01.

CRVS Stock Stochastic Average

Today, Corvus Pharmaceuticals Inc’s raw stochastic average for the past 50 days stands at 68.53%, indicating a rise from the raw stochastic average of the last 20 days, which was 48.59%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 38.37% and 34.33% respectively.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts